OM

$4.25-$0.25 (-5.56%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$84.6M

19M shares

52-week range

$3.00 – $16.16

9% from low

Sector

ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS

Exchange

NASDAQ

Change$-592.75

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$126M	+7.2%	$-2.91	$-2.94–$-2.88	—	2
2027	$139M	+10.8%	$-2.18	$-2.25–$-2.11	—	2
2028	$153M	+9.9%	$-1.77	$-1.79–$-1.76	—	1
2029	$173M	+13.0%	$-1.17	$-1.18–$-1.16	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 2 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-06	$-0.72	$-0.80	-11.6%
2026-05-07	$-0.79	$-0.83	-5.1%
2026-02-11	$-0.67	$-0.84	-24.7%
2025-11-10	$-0.66	$-0.69	-5.3%
2025-08-06	$-0.98	$-0.84	+14.5%
2025-05-07	$-0.94	$-3.24	-242.9%
2025-02-19	$-6.20	$-5.55	+10.5%
2024-11-06	$-0.40

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
OMOutset Medical, Inc.	$4.57	+1.44%	$85M	—
CATXPerspective Therapeutics, Inc.	$3.19	-2.30%	$363M	—
HSDTSolana Company	$1.77	+1.72%	$103M	—
INGNInogen, Inc.	$5.81	-0.17%	$157M	—
NNOXNano-X Imaging Ltd.	$1.01	-0.98%

Outset Medical, Inc. Common Stock

Outset Medical Inc is a medical technology company pioneering a technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.

www.outsetmedical.com

Employees: 310
IPO / List date: Sep 15, 2020
HQ: SAN JOSE, CA

Held by traders on TradeandTell

No one on the platform currently holds OM.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	222,075	$852.8K

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Stock splits

Execution date	Ratio
2025-03-20	1-for-15reverse

Recent trades on TradeandTell

No one on the platform has traded OM yet.

$OM chatter on StockTwits

Giuseppe Marino@giu_ve2d
$OM shorts pile up when SP is above 5$. They usually win...
View on StockTwits ↗
Giuseppe Marino@giu_ve3d
$OM 👁️👁️
View on StockTwits ↗
Michael Lerner@MikeyNJ6d
$OM this remains a long term speculative play. It will be bid up when there is a clear inflection point. This earnings didn't do it.
View on StockTwits ↗
Giuseppe Marino@giu_veAug 7
$OM if SP goes south today, you can just call it manipulation
View on StockTwits ↗
SEACAI@SEACAIBullishAug 6
$OM overall, I like the outcome and the call. I still think they are too conservative (and the first question in Q&A tried to dislodge the conservatism, but to no avail). But fair enough, they upped the guidance at the Q2 ER last year only to post a mild reduction in capital sales in Q3 (which shifted to Q4) and the stock got hammered as an over reaction. Given the refresh and the elevated utilization that they mention and very high installation in Q2 (ie consummables revenue), I expect that they will exceed the targets for Q3 and then Q4 will come strong as it usually does. My only concern is in the potential delay of the full launch of Tablo 2.0 as they try to perfect the product (I am still hoping for early Q3 full launch).
View on StockTwits ↗
Michael Lerner@MikeyNJAug 6
$OM bottom line, the quarter was fine. They have adequate cash and remain optimistic that over time, they will execute the business plan to profitability. At less than one times revenue, the stock is cheap. The problem is that investors are impatient. This is a typical case where the CEO buying shares on the open market would do wonders for the stock price. Not holding my breath.
View on StockTwits ↗
Giuseppe Marino@giu_veAug 6
$OM 31.6 millions better than 2nd quarter 2025 (31.4). I take it....
View on StockTwits ↗
Shrikant Bhaiya@TechnicalcharterAug 6
$OM keeping same guidance is not a good idea. They had to give something to cheer now it’s up to the call and how bullish they sound.
View on StockTwits ↗
Stocktwits Earnings@StocktwitsEarningsAug 6
$OM Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.97 up 6.73% YoY • Reported revenue of $31.64M up 0.69% YoY • Outset Medical reiterated its 2026 revenue guidance of $125 million to $130 million, representing a 5% to 9% increase over 2025, and expects non-GAAP gross margin in the low-40% to mid-40% range.
View on StockTwits ↗
Shaun Oliver@ShaunmanOAug 5
$CLOV Hopefully $OM will have a similar ER tomorrow. My second largest holding behind Clov.
View on StockTwits ↗
Giuseppe Marino@giu_veAug 5
$OM ER tomorrow. Will the MFs who have been manipulating SP for so long let SP above 5$ for 2/3 consecutive days. Shorts have covered half of the shares wrt previous month, good sign? Tomorrow night we shall know....
View on StockTwits ↗
Shrikant Bhaiya@TechnicalcharterBullishAug 4
$OM this has been a long consolidation between 3 and 6.5; if everything goes well; this should go to 11.4 this month.
View on StockTwits ↗
Michael Lerner@MikeyNJAug 4
$OM They hinted about getting more clarity on the new contracts last call. If they can confidently now raise guidance, this should gap up significantly. We will see tomorrow.
View on StockTwits ↗
Tony@DrZingoBullishAug 3
$OM
View on StockTwits ↗
jorge .miguel@focafoca99Jul 29
$OM cautions investors that a law firm is probing potential fiduciary breaches by its officers and directors.
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.